Tag: PD-(L)1 inhibitor
Updated results of CameL-sq trial confirm benefit of camrelizumab
No long-term benefit of adding ipilimumab to pembrolizumab in metastatic NSCLC
In concurrent CRT for stage III, unresectable NSCLC, performance status is better with proton therapy than photon therapy
No improved prognosis for concurrent versus sequential immune checkpoint inhibition and CRT in unresectable NSCLC
Durvalumab after sequential CRT safe in stage III, unresectable NSCLC
No impact of grade ≥2 pneumonitis on patient-reported outcomes in PACIFIC
Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC
Characteristics of long-term survivors in the CASPIAN trial
Outcomes of real-world CANTABRICO trial match results from CASPIAN
No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma
Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma
First-line avelumab shows clinical activity in advanced urothelial carcinoma
Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma
Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer
High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib
DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up
Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC
Combined nivolumab/axitinib treatment elicits good response in metastatic RCC
Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC
Atezolizumab does not improve survival in advanced penile cancer
AK104 plus chemotherapy promising first-line option for gastric cancer
Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome
Updates on pembrolizumab for oesophageal and gastric cancer
NIPICOL: New data on optimal ICI treatment duration in MSI/dMMR mCRC
Dostarlimab may offer an alternative for dMMR rectal cancer
Nivolumab plus standard-of-care does not meet primary endpoint for mCRC
Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma
TOPAZ-1: Adding durvalumab to chemotherapy effective in advanced biliary tract cancer
HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC
Double-positive results for triple-negative metastatic breast cancer
Immune chemo-sensitisation looks promising in microsatellite-stable mCRC
Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer
ctDNA highly predictive in HER2-positive, advanced gastric or gastro-oesophageal junction cancer
Nivolumab/ipilimumab continues to provide survival benefit in unresectable MPM
Adjuvant atezolizumab lowers relapse rate in resected NSCLC
Three-year OS follow-up from CASPIAN trial
TCR clonality predicts pembrolizumab response in NSCLC
Adjuvant immunotherapy reduces risk of disease recurrence in stage II melanoma
IFN-γ signature predicts response to immunotherapy
Updated results of SECOMBIT trial
Combining T-VEC and pembrolizumab does not significantly improve survival in advanced, unresectable melanoma
Durable intracranial responses with nivolumab/ipilimumab
Modified ipilimumab schedule reduces risk of grade 3/4 adverse events
Optimal neoadjuvant dose ipilimumab/nivolumab in stage III urothelial cancer
Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer
Pembrolizumab has durable effect in previously treated MSI-H/dMMR advanced endometrial cancer
Low numbers of M2 macrophages in tumour microenvironment associated with superior response to immunotherapy in Hodgkin lymphoma
Neutrophils negatively correlate with response to anti-PD-1 monotherapy in dMMR tumours
Trial explores potential benefit of adding atezolizumab to usual care for mesothelioma
Neoadjuvant nivolumab plus chemotherapy improves surgical outcomes in NSCLC
Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer
Novel dual checkpoint blockade improves progression-free survival in melanoma
Immune-related adverse events are associated with efficacy of atezolizumab in patients with advanced NSCLC
Sustained efficacy of nivolumab/ipilimumab plus 2 cycles of chemotherapy in NSCLC
Post-nephrectomy pembrolizumab improves disease-free survival
Benefit of both I-O/chemo combo and I-O/I-O combo over chemotherapy alone in oesophageal squamous cell cancer
Benefit of I-O/chemo combo over chemotherapy alone in advanced GC/GEJC/EAC
Promising efficacy and safety of feladilimab in recurrent/metastatic urothelial carcinoma
Neoadjuvant therapy with nivolumab plus relatlimab is safe and effective in patients with stage III melanoma
Durvalumab after chemoradiation proven safe in elderly NSCLC patients
Doubling overall survival in US veterans with stage 3 non-small cell lung cancer
5-year PACIFIC data hold strong in NSCLC
Early-Stage NSCLC: Promising Data for Neoadjuvant Durvalumab With Stereotactic Body Radiotherapy
Novel imaging biomarkers predict benefit in stage 3 NSCLC treated with chemoradiation and durvalumab
T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Chemoimmunotherapy is effective in a subset of small cell lung cancer patients
